Evinacumab is approved as adjunct therapy for HoFH and is used to reduce which lipids?

Enhance your knowledge of antihyperlipidemics and lipid management. Study with multiple choice questions and detailed explanations. Ace your test!

Multiple Choice

Evinacumab is approved as adjunct therapy for HoFH and is used to reduce which lipids?

Evinacumab works through a mechanism that lowers lipid levels in a way that doesn’t rely on the LDL receptor. It’s a monoclonal antibody against ANGPTL3, and by inhibiting ANGPTL3, it reduces the production and increases the clearance of triglyceride-rich lipoproteins. In people with homozygous familial hypercholesterolemia (HoFH), where LDL receptor function is severely impaired, this leads to meaningful reductions in LDL-C as well as triglycerides, independent of LDL receptor status. Because of this unique action, it is approved specifically as adjunct therapy for HoFH. It’s not used as first-line therapy for hypertriglyceridemia, nor is it a treatment for hypertension or diabetes. In trials, LDL-C reductions in HoFH have been substantial (roughly 40–60%), with additional triglyceride reductions, which explains its role as an adjunctive option in this very high-risk group.

Evinacumab works through a mechanism that lowers lipid levels in a way that doesn’t rely on the LDL receptor. It’s a monoclonal antibody against ANGPTL3, and by inhibiting ANGPTL3, it reduces the production and increases the clearance of triglyceride-rich lipoproteins. In people with homozygous familial hypercholesterolemia (HoFH), where LDL receptor function is severely impaired, this leads to meaningful reductions in LDL-C as well as triglycerides, independent of LDL receptor status. Because of this unique action, it is approved specifically as adjunct therapy for HoFH. It’s not used as first-line therapy for hypertriglyceridemia, nor is it a treatment for hypertension or diabetes. In trials, LDL-C reductions in HoFH have been substantial (roughly 40–60%), with additional triglyceride reductions, which explains its role as an adjunctive option in this very high-risk group.

More practice questions